PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A

INTRODUCTION: BAY 94‐9027, a site‐specifically PEGylated, B‐domain‒deleted recombinant factor VIII (FVIII) with extended half‐life, demonstrated efficacy for bleed prevention and treatment in previously treated adolescents and adults with severe haemophilia A. AIM: To assess BAY 94‐9027 in children...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haemophilia
Autors principals: Santagostino, Elena, Kenet, Gili, Fischer, Kathelijn, Biss, Tina, Ahuja, Sanjay, Steele, MacGregor, Martínez, M., Male, C., van Geet, C., Mondelaers, V., Kaleva, V., Stoyanova‐Deleva, A., Bobev, D., Blanchette, V., Zanon, E., Gagliano, F., Rageliene, L., Peters, M., Mlynarski, W., Badowska, W., Serban, M., Rusen, L., Uscatescu, V., Will, A., Payne, J., Tunstall, O., Kerlin, B., Gruppo, R., Eyster, M. E., Ducore, J., Schwartz, J.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7317355/
https://ncbi.nlm.nih.gov/pubmed/32212300
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/hae.13963
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars